Cencora (COR) FY2025 10-K Annual Report
Cencora (COR) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Nov 25, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Cencora FY2025 10-K Analysis
Business Overview
- • Core business: Pharmaceutical distribution competing with manufacturers, chain drugstores, specialty distributors, packaging, and healthcare technology firms
- • Emphasized regulatory compliance due to new U.S. and EU laws (DSCSA, Falsified Medicines Directive, EU Critical Medicines Act, EU HTA Regulation effective Jan 2025)
- • Strategic focus on managing risks from opioid regulation, drug pricing reforms (Inflation Reduction Act, OBBBA), and 340B pricing program disputes and pilot rebate models
- • Two largest trade receivables (Walgreens/Boots and Evernorth) represent approx. 43% of net accounts receivable as of Sept 30, 2025
- • Noteworthy: Adoption of EU HTA Regulation harmonizing drug assessments starts Jan 12, 2025, with potential major impact on reimbursement decisions and market access
Management Discussion & Analysis
- • Revenue $321.3B, up 9.3% YoY; U.S. Healthcare Solutions revenue $291.0B, up 9.7% ($25.6B increase); International Solutions $30.4B, up 6.1% ($1.7B increase)
- • Operating margin total 0.82% approx. (operating income $2.63B / revenue $321.3B); U.S. Healthcare margin 1.23%, up 12 bps YoY; International margin decreased 9.1% YoY
- • Best segment: U.S. Healthcare Solutions operating income $3.57B, up 21.8% ($639.8M increase); worst segment: International Healthcare Solutions operating income $648M, down 9.1% ($65.1M decrease)
- • Cash from operations $3.9B in fiscal 2025, capex $668M; acquisitions $3.9B for RCA; dividends $437.1M paid; share repurchases $435.5M with $882.2M authorization remaining
- • Management expects ~$900M capex in 2026; key risks include nonrenewal of customer contracts, opioid litigation payments of $4.3B over 13 years, interest rate and foreign currency exposure, inflation pressures, and geopolitical uncertainties
Risk Factors
- • Board oversight of cybersecurity delegated to Audit Committee and Compliance and Risk Committee with quarterly meetings and ongoing updates
- • CDIO with 25+ years experience and CISO with 20+ years oversee cybersecurity risk management and incident response
- • Extended Cyber Crisis Response Team leads containment, recovery, and communication during cyber incidents
- • Cybersecurity risk identified by Enterprise Risk Management Team for Board-level oversight and regular risk monitoring
Cencora FY2025 Key Financial MetricsXBRL
Revenue
$321.3B
▲ +9.3% YoY
Net Income
$1.6B
▲ +3.0% YoY
Gross Margin
3.6%
▲ +20bp YoY
Operating Margin
0.8%
▲ +8bp YoY
Net Margin
0.5%
▼ -3bp YoY
ROE
103.1%
▼ -13057bp YoY
Total Assets
$76.6B
▲ +14.1% YoY
EPS (Diluted)
$7.96
▲ +5.7% YoY
Operating Cash Flow
$3.9B
▲ +11.2% YoY
Source: XBRL data from Cencora FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Cencora
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.